Project Grant R01HD113450

Award Date 9/13/24
Completion Date 5/31/29
Dollars Obligated $20K
Funding Federal Agency
Fogarty International Center
Federal Grant Program
93.989
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
This $1,161,154 project grant award from the National Institute on Aging (NIA), under the Aging Research (CFDA 93.866) program, aims to develop a regenerative "dendritic spine-targeted" therapeutic approach to address HIV-1-associated neurocognitive disorders (HAND) in older adults. Key objectives include: Establishing efficacious "dendritic spine-targeted" therapeutics, such as the isoflavandiol estrogen S-equol (SE) and a specific estrogen B-receptor agonist (SERBA), to...
This $756,077 Project Grant was awarded by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The grant supports a 5-year research study to investigate the long-term immunologic, cardiovascular, metabolic, and neurocognitive outcomes in children and adolescents with perinatal HIV infection who have achieved viral suppression on long-term antiretroviral therapy. The research will assess...
This Project Grant award, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), supports a comprehensive study to determine the prevalence and clinical characteristics of mild cognitive impairment (MCI) and Alzheimer's-related dementia (ADRD) among older adults living with HIV in Uganda. The $1,103,953 award, which began on Sep 15, 2024 and runs through Aug 31, 2025, will fund the following key activities: Comprehensive neuropsychological assessments among 600 older...
This federal Project Grant award of $403,488 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) supports research to investigate the impact of HIV and antiretroviral therapy (ART) on glial cell lipid metabolism and its effect on myelination during adolescence. The research aims to determine how HIV and ART disrupt oligodendroglial and astroglial lipid metabolism, which is essential for proper myelination, a critical process during...
This $1,454,724 Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), aims to understand the mechanisms involved in HIV-1 latency in the central nervous system (CNS). The primary objectives are to identify key factors, pathways, and regulators that determine the establishment, maintenance, and reactivation of latent HIV-1 virus in brain myeloid cell lineages, such as microglia and macrophages. The research will...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $2,210,865 to the University of California, Los Angeles (UCLA) to study the unique neural and inflammatory mechanisms of depression in people living with HIV (PLWH). The study aims to elucidate how HIV status, inflammation, and depression interact with critical brain networks, with the goal of identifying potential biomarkers and treatment targets....
This $823,691 Project Grant award was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to investigate the role of immune checkpoints in the central nervous system (CNS) of people living with HIV (PLWH) and their association with HIV-associated neurocognitive disorder (HAND). The research aims to determine the profiles and biological functions of soluble immune checkpoints (sICPs) in the CNS of PLWH and a simian immunodeficiency...
This Project Grant award for $665,171.00, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to improve outcomes for individuals with HIV-associated opportunistic infections like cryptococcal and TB meningitis. The key objectives are to: 1) define CSF drug concentrations or AUC/MIC ratios that predict fungal clearance, 2) determine the relationship between...
The National Institutes of Health (NIH), through the Mental Health Research Grants program (CFDA 93.242) administered by the National Institute of Mental Health (NIMH), has awarded a $434,500 R21 grant to the University of California, San Diego (UCSD) to investigate the epigenetic mechanisms controlling HIV latency and neuropathogenesis in microglia. The project aims to use single-cell multi-omics approaches and state-of-the-art sequencing technologies to characterize the transcriptomic and...
The National Institute on Drug Abuse (NIDA) awarded a $2,223,769 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of California, San Diego (UCSD) to investigate the individual and combined impact of HIV and opioids on inflammasome-mediated neuroinflammation and neurotoxicity. The 5-year study, which commenced on April 15, 2025, aims to uncover the mechanistic intersection between HIV and opioids that leads to more severe neurological...

ENHANCING NOVEL RESEARCH FOR INFLAMMATION AND COGNITIVE HEALTH AMONG ADOLESCENTS AND YOUNG ADULTS LIVING WITH PERINATALLY ACQUIRED HIV AND ADVERSITY (ENRICH+) - NEUROCOGNITIVE IMPAIRMENT (NCI) IS ONE OF THE MOST PREVALENT AND DELETERIOUS COMPLICATIONS OBSERVED IN ADOLESCENTS AND YOUNG ADULTS (AYA) WITH PERINATALLY ACQUIRED HIV (PHIV), EVEN DESPITE VIRAL SUPPRESSION. GAPS IN OUR CURRENT UNDERSTANDING OF WHAT DRIVES NCI IN VIRALLY SUPPRESSED PEOPLE WITH PHIV GREATLY LIMIT OUR ABILITY TO DEVELOP TARGETED AND TAILORED INTERVENTIONS FOR IT. A GROWING BODY OF RESEARCH INDICATES THAT IMMUNE DYSFUNCTION (ID) MAY DRIVE NCI IN VIRALLY SUPPRESSED HIV. PERIPHERAL BLOOD MARKERS OF PERSISTENT AND CHRONIC ID (I.E., INFLAMMATION [E.G., CCL2, IL-8, AND TNF-A] AND IMMUNE ACTIVATION [E.G., SCD14, SCD163]) ARE HIGHER IN PEOPLE WITH HIV AND ASSOCIATED WITH NCI. THE PREPONDERANCE OF THIS RESEARCH, THOUGH, HAS BEEN AMONG ADULTS WITH HORIZONTALLY ACQUIRED HIV (HHIV) FROM HIGH-INCOME COUNTRIES. HHIV IS DISTINCTLY DIFFERENT THAN PHIV WHERE INFECTION BEGAN PRIOR TO PHYSIOLOGICAL, IMMUNOLOGICAL AND BRAIN DEVELOPMENT. NON-HIV SOURCES OF ID, SUCH AS MEDICAL (E.G., MALARIA, SARS-COV-2), SOCIAL (E.G., EARLY TRAUMA, STIGMA, POVERTY), AND ENVIRONMENTAL (E.G., AIR POLLUTION) ADVERSITIES ARE ALSO ALL INDEPENDENTLY ASSOCIATED WITH NCI BUT HAVE BEEN OVERLOOKED AS POTENTIAL MODIFIERS OF ID ON NCI IN HIV. YET, MANY PEOPLE WITH PHIV EXPERIENCE A HIGH BURDEN OF THESE ADVERSITIES, ESPECIALLY IN UGANDA - WHERE THE PROPOSED STUDY WILL TAKE PLACE - AND OTHER COUNTRIES IN SUB-SAHARAN AFRICA (SSA). ENDURING MULTIPLE CO-OCCURRING ADVERSITIES (I.E., SYNDEMICS) AS WELL AS TIMING, DURATION AND TYPE OF ART, MAY AFFECT THE RELATIONSHIPS BETWEEN HIV AND ID, AND THUS NCI, DIFFERENTLY IN PHIV VS HHIV, BUT RESEARCH HAS NOT ADDRESSED THIS. TO DATE, MOST STUDIES ON ID AND NCI IN HIV HAVE FOCUSED ON HOST AND GENETIC FACTORS, WHILE OVERLOOKING CONTEXTUAL FACTORS KNOWN TO CONTRIBUTE TO ID AND NCI. NO STUDIES TO DATE HAVE DIRECTLY COMPARED ID AND NCI IN AYA POPULATIONS OF THE SAME AGE WITH PHIV AND HORIZONTALLY ACQUIRED HIV IN SSA. MAKING THIS COMPARISON WILL ALLOW US, FOR THE FIRST TIME, TO DELINEATE HOW LIFELONG HIV INFECTION ACQUIRED PRIOR TO KEY PHYSIOLOGICAL, IMMUNOLOGICAL AND BRAIN DEVELOPMENT, AS WELL AS TIMING, DURATION AND TYPE OF ART, MAY ALTER IMMUNE SYSTEM RESPONSES AND HOW NCI MANIFESTS IN ADOLESCENCE AND YOUNG ADULTHOOD, AS WELL AS HOW EXPOSURE TO CHRONIC ADVERSITY MAY AFFECT THE RELATIONSHIP BETWEEN ID AND NCI IN HIV-INFECTION. ADDRESSING THIS KNOWLEDGE GAP IS CRITICAL TO DEVELOPING TARGETED AND DEVELOPMENTALLY APPROPRIATE INTERVENTIONS FOR NCI IN AYA WITH PHIV, AS THE EFFECTS OF EXPOSURE TO INDIVIDUAL AND COMBINED ADVERSITIES MAY IMPACT ID AND NCI DIFFERENTLY IN AYA WITH PHIV. NOT ONLY WILL THIS STUDY HELP DETERMINE CRITICAL INTERVENTION TARGETS FOR ID AND NCI, IT WILL ALSO COHERE A GROUP OF EARLY AND ESTABLISHED UGANDAN AND US INVESTIGATORS FOCUSED ON OPTIMIZING AYA OUTCOMES AND PROVIDE RESEARCH OPPORTUNITIES AND MENTORSHIP TO MEDICAL, PSYCHIATRY AND PSYCHOLOGY STUDENTS AT MAKERERE UNIVERSITY FOR COLLABORATIVE DEVELOPMENT OF NEXT-GENERATION US AND UGANDAN TRAINEES IN BRAIN HEALTH AND ID ACROSS THE LIFESPAN.

Posted 9/13/24, 12:00 AM